Advertisement
Advertisement
MBX
MBX Biosciences, Inc. Common Stock
40.08
USDSponsored
-0.89
-2.16%
May 11, 15:59 UTC -4
Closed
After-Market
40.13
+0.05
+0.12%
MBX Earnings Reports
Positive Surprise Ratio
MBX beat 6 of 7 last estimates.
86%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.65
Implied change from Q1 26 (Revenue/ EPS)
--
/+27.45%
Implied change from Q2 25 (Revenue/ EPS)
--
/+14.04%
MBX Biosciences, Inc. Common Stock earnings per share and revenue
On May 07, 2026, MBX reported earnings of -0.51 USD per share (EPS) for Q1 26, beating the estimate of -0.58 USD, resulting in a 13.32% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +8.06% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.65 USD, with revenue projected to reach -- USD, implying an increase of 27.45% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Oculis Holding AG Ordinary shares
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.42
Actual
-$0.49
Surprise
-15.83%
Bicara Therapeutics Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.66
Actual
-$0.93
Surprise
-39.98%
Enanta Pharmaceuticals, Inc
Report Date
May 11, 2026 For Q2 26
Estimate
-$0.49
Actual
-$0.45
Surprise
+9.60%
Cellectis S.A. - ADR
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.28
Actual
-$0.18
Surprise
+36.03%
Coherus Oncology, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+10.33%
Elicio Therapeutics, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.47
Actual
-$0.65
Surprise
-37.04%
Agenus Inc.
Report Date
May 11, 2026 For Q1 26
Estimate
$2.14
Actual
$1.02
Surprise
-52.38%
Erasca, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+48.38%
Liquidia Corporation Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
$0.41
Actual
$0.52
Surprise
+24.31%
Kyntra Bio, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$3.42
Actual
-$3.74
Surprise
-9.29%
FAQ
What were MBX Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, MBX Biosciences, Inc. Common Stock reported EPS of -$0.51, beating estimates by 13.32%, and revenue of $0.00, 0% as expectations.
How did the market react to MBX Biosciences, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 8.06%, changed from $32.12 before the earnings release to $34.71 the day after.
When is MBX Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for MBX Biosciences, Inc. Common Stock's next earnings report?
Based on --
analysts, MBX Biosciences, Inc. Common Stock is expected to report EPS of -$0.65 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement